Regarding third-line therapy for EGFR-mutant NSCLC patients, previously treated with EGFR-TKI and platinum-based chemotherapy, a novel antibody-drug conjugate patritumab deruxtecan, or HER3-DXd, has been evaluated in the phase II HERTHENA-Lung01 [104]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.